Leukapheresis Market Size, Share, Growth Analysis, By Product Type(Leukapheresis devices and leukapheresis disposables), By Application(Leukemia, lymphoma), By End user(Hospitals and blood component centers, pharmaceutical and biotechnology companies) - Industry Forecast 2024-2031

Leukapheresis Market size was valued at USD 65.60 billion in 2021 and is poised to grow from USD 71.44 billion in 2022 to USD 141.30 billion by 2030, growing at a CAGR of 8.9% during the forecast period (2023-2030).

Leukapheresis Market features a highly competitive landscape with the presence of several key players striving to gain a larger market share. Companies in this market are focused on product development, strategic collaborations, mergers and acquisitions, and geographic expansion to strengthen their position in the market. Some prominent players in the leukapheresis market are consistently investing in research and development activities to introduce innovative leukapheresis products and technologies. They are also engaged in partnerships and collaborations with healthcare institutions and research organizations to further expand their product offerings and explore new market opportunities. With the increasing prevalence of blood-related disorders and the rising demand for leukapheresis procedures, the competitive landscape of the leukapheresis market is expected to witness further advancements and intense competition among the key market players. 'Terumo BCT Corporation (US)', 'Asahi Kasei Medical Co., Ltd. (Japan)', 'Fresenius SE & Co. KGaA (Germany)', 'Haemonetics Corporation (US)', 'Macopharma SA (France)', 'Miltenyi Biotec GmbH (Germany)', 'STEMCELL Technologies Inc. (Canada)', 'Cytiva (US)', 'Beijing ZKSK Technology Co., Ltd. (China)', 'Grifols, S.A. (Spain)', 'Kaneka Corporation (Japan)', 'Medica SpA (Italy)', 'B. Braun Melsungen AG (Germany)', 'Immucor, Inc. (US)', 'Bioelettronica S.r.l. (Italy)', 'Fresenius Kabi AG (Germany)', 'Qingdao Huarui Biological Technology Co., Ltd. (China)', 'Miltenyi Biotec B.V. & Co. KG (Netherlands)', 'Therakos, Inc. (US)', 'Pluristem Therapeutics Inc. (Israel)'

The rising incidence of hematologic disorders, such as leukemia and lymphoma, is a significant driver for the leukapheresis market. These diseases require effective treatment approaches, and leukapheresis plays a crucial role in managing abnormal white blood cell counts. For example, in cases of acute leukemia, leukapheresis can rapidly reduce the number of leukemic cells in the blood to alleviate symptoms and prepare patients for subsequent therapies.

Integration of Leukapheresis with Cell-Based Therapies: Leukapheresis is increasingly integrated with cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy involves the collection and genetic modification of a patient's own white blood cells, which are then infused back into the patient to target and eliminate cancer cells. Leukapheresis plays a vital role in obtaining the required cells for CAR T-cell therapy, making it an integral part of the treatment process.

North America dominated the leukapheresis market, driven by advanced healthcare infrastructure, strong research and development capabilities, and high adoption of innovative medical technologies. The region benefits from the presence of key market players, academic institutions, and research centers focused on advancing leukapheresis procedures. For instance, the United States dominates the North American market with a considerable market share. The country's well-established healthcare system, supportive regulatory environment, and increasing prevalence of hematologic disorders contribute to the market's dominance. Another dominating region is Europe, which holds a significant market share in the leukapheresis market. European countries such as Germany, France, and the United Kingdom have well-developed healthcare systems and robust research activities. These countries have a high adoption rate of advanced medical technologies and a strong focus on precision medicine, which drives the demand for leukapheresis procedures.